CREANT is part of the IPPON Research Center of Excellence, a consortium whose research activities are at the forefront of integrated personalized cancer medicine. For different cancers in urgent need for improved therapeutic outcomes, our joint mission is:

  • To develop novel and more effective therapeutic strategies;
  • To improve the detection and understanding of mechanisms driving therapeutic resistance;
  • To identify and validate biomarkers for early detection and personalized

The strong interdisciplinary partnership between basic, translational and clinical researchers within the IPPON consortium enables us to tackle burning research questions and clinical unmet needs and leads us to meaningful advances in the highly innovative and rapidly changing field of personalized cancer medicine and to improved patient outcomes both in terms of survival and quality of life.